THE MODERATING EFFECTS OF DEPRESSION ON BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS

被引：0
|
作者：
Rathbun, A. M. [1 ]
Harrold, L. R. [2 ]
Reed, G. W. [1 ]
机构：
[1] Univ Massachusetts, Sch Med, Med, Worcester, MA 01605 USA
[2] Univ Massachusetts, Sch Med, Orthoped, Worcester, MA 01605 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2014年 / 73卷
关键词：
D O I：
10.1136/annrheumdis-2014-eular.3422
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0112
引用
收藏
页码：631 / 631
页数：1
相关论文
共 50 条
  • [21] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Monchablon, Clelia
    Gonde, Henri
    Pouplin, Sophie
    Varin, Remi
    Vittecoq, Olivier
    Lequerre, Thierry
    CLINICAL RHEUMATOLOGY, 2020, 39 (01) : 207 - 216
  • [22] PREDICTIVE FACTORS FOR SUCCESSFUL BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS DOSE TAPERING IN RHEUMATOID ARTHRITIS
    Loh, Min Yi
    Jones, Claire J.
    Peall, Adrian
    Trickey, Jeanette
    RHEUMATOLOGY, 2023, 62
  • [23] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Fleischmann, Roy
    CLINICAL RHEUMATOLOGY, 2021, 40 (11) : 4369 - 4372
  • [24] Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis
    Sendaydiego, Xavier
    Gold, Laura
    Wysham, K.
    Liew, Jean
    Dubreuil, Maureen
    Andrews, James
    Reid, Pankti
    Liew, David
    Goulabchand, Radjiv
    Singh, Abha
    Hughes, Grant
    Pioro, Mathilde
    Sparks, Jeffrey
    Jarvik, Jeffrey
    Singh, Siddharth
    Singh, Namrata
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 848 - 850
  • [25] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    Clinical Rheumatology, 2020, 39 : 207 - 216
  • [26] EVALUATION OF ADHERENCE TO BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH INFLAMMATORY ARTHRITIS
    Lim, Y. C.
    Teo, W. G.
    Eng, M. N.
    Cheen, H. M.
    Tay, X. Y.
    Yeo, S. I.
    Lim, T. G.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1800 - 1800
  • [27] Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis
    Min, Hong Ki
    Kim, Se Hee
    Kim, Hae-Rim
    Lee, Sang-Heon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [28] Cardiovascular Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs (DMARDs)
    Drakopoulou, Maria
    Soulaidopoulos, Stergios
    Oikonomou, George
    Tousoulis, Dimitrios
    Toutouzas, Konstantinos
    CURRENT VASCULAR PHARMACOLOGY, 2020, 18 (05) : 488 - 506
  • [29] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
    Shimada, Hiromi
    Kameda, Tomohiro
    Kanenishi, Kenji
    Miyatake, Nobuyuki
    Nakashima, Shusaku
    Wakiya, Risa
    Kato, Mikiya
    Miyagi, Taichi
    Mansour, Mai Mahmoud Fahmy
    Hata, Toshiyuki
    Kadowaki, Norimitsu
    Dobashi, Hiroaki
    CLINICAL RHEUMATOLOGY, 2019, 38 (05) : 1453 - 1458
  • [30] Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
    Tawaratsumida H.
    Setoguchi T.
    Arishima Y.
    Ohtsubo H.
    Akimoto M.
    Ishidou Y.
    Nagano S.
    Taketomi E.
    Sunahara N.
    Komiya S.
    BMC Research Notes, 10 (1)
12345